In 2020, tazemetostat (Tazverik), a first-in-class small molecule EZH2 inhibitor, was granted accelerated approval by the FDA for patients with advanced or metastatic epithelioid sarcoma who are not eligible for curative surgery. The gene discussed is EZH2; the disease is epithelioid sarcoma.